Episode 291: ASCO GU 2024 - CONTACT-02; Cabozantinib and Atezolizumab in Prostate Cancer

Neeraj Agarwal, MD, FASCO, describes the results of the phase III CONTACT-02 trial on cabozantinib plus atezolizumab in prostate cancer.
Dr. Agarwal serves as a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, and directs the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the HCI.